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annually. Two-way sensitivity analyses were performed by varying values for 
key parameters in the model. RESULTS: Under base-case scenario, gain of QALYs 
per patient associated with exemestane (29 QALYS) was higher compared with 
tamoxifen (28 QALYS) and raloxifene (28 QALYS). The cost of gaining one QALY 
with exemestane ($44,723) was found to be low compared to tamoxifen ($93,053) 
and raloxifene ($70,940). These results were robust to the two-way sensitivity 
analyses performed. CONCLUSIONS: Results suggested that switching to 
exemestane after 2 years of primary treatment with tamoxifen was cost-
effective.  
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OBJECTIVE: Colorectal cancer (CRC) is one of the leading causes of cancer-related 
deaths in Australia and a common cause of morbidity and mortality worldwide. 
Screening is an attractive option since there is an identifiable precursor lesion 
and the bowel is readily accessible for screening. In addition, the early detecting 
of CRC or adenoma has been proven to reduce CRC-associated mortality. The 
faecal-occult blood test (FOBT) is a widely-used cost-effective screening tool for 
large-scale bowel cancer screening programs. In 2006, a National Bowel Cancer 
Screening Program (NBCSP) was established in Australia, using an 
immunochemistry-based FOBT. The Program currently targets all Australians 
who turn 50, 55 or 65 years of age between January 2011 and December 2014. 
Despite the proven impact of screening on reducing bowel cancer mortality, the 
uptake of the NBCSP has been low. OBJECTIVES: To evaluate the cost-
effectiveness of a patient-direct mailed advance notification letter, on 
participants of the NBCSP in Australia. METHODS: This study followed a 
hypothetical cohort of 50-year-old, 55-year-old and 65-year-old patients 
undergoing FOBT screening through a Decision analytic Markov model. The 
intervention compared two strategies: 1) Advance letter, NBCSP and FOBT 
compared with 2) NBCSP and FOBT. The main outcome measures were life years 
gained (LYG), quality-adjusted life years (QALY) gained and incremental cost-
effectiveness ratio (ICER). RESULTS: An advance notification screening letter 
would yield an additional 54 per 100,000 CRC deaths avoided compared with no 
letter. The estimated cost-effectiveness was $3976 per LYG and $6976 per QALY 
gained. CONCLUSIONS: An advance notification letter in the NBCSP may have a 
significant impact on life years gained and cancer deaths avoided. It is cost-
effective and offers a feasible strategy that could be rolled out across other 
screening program at an acceptable cost.  
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OBJECTIVES: The escalating cost of innovative new cancer therapies has 
received increased attention in the medical literature and popular press. Cost-
utility analyses (CUAs) provide information on value for money and are widely 
published in medical and economic literature. We describe the growth over time 
of cancer-related CUAs and the cost-effectiveness of new FDA approved 
interventions. METHODS: We systematically searched the Tufts Cost-
Effectiveness Analysis Registry (www.cearegistry.org) for original cancer-related 
CUAs published through 2010. In addition to overall descriptive statistics, we 
analyzed the cost-effectiveness of all FDA- approved cancer therapies from 2000 
to 2010. RESULTS: We identified 493 cancer-related CUAs from 2000-2010 (16%  
of all studies in the Registry during that time period). The number of cancer 
studies has increased dramatically; since 2006, the total has more than doubled. 
Among cancer therapies approved by the FDA from 2000 to 2010, over 50% had 
relevant cost-utility ratios. Among CUAs focused on newly-approved therapies, 
55% were sponsored by industry compared to 21% industry-sponsorship of 
studies focused on all other therapies, which includes non-drug and older  
and non-approved FDA therapies. The median reported cost-effectiveness ratio 
(US$2010) was $28,000 for all cancer studies. For therapies approved by the FDA 
from 2000 to 2010 the median ICER was $29,000. For newly-approved therapies, 
industry sponsorship was associated with a median ICER of $23,000 compared  
to $49,000 for non-industry sponsored studies (p=.01). CONCLUSIONS:  
The number of CUAs related to cancer continues to grow. Despite high costs, 
many newly-approved therapies have ratios reflecting relatively good value for 
money; however, many new therapies’ have not had cost-utility analyses 
published.  
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OBJECTIVES: Recurrent disease represents a clinical challenge in the treatment 
of indolent non-Hodgkin’s lymphoma (iNHL) and mantle cell lymphomas (MCL). 
The combination of fludarabine+rituximab (FR) is among the current treatments 
for relapsed iNHL and MCL. The objective of this study was to assess the 
economic impact of bendamustine-rituximab (BR) compared to FR in the 
treatment of relapsed iNHL and MCL in Canada. METHODS: The cost-
effectiveness of BR compared to FR in the treatment of relapsed iNHL/MCL was 
assessed over a lifetime horizon using a time-dependent Markov model. The 
Markov model comprises three health states: progression-free (PF), progressive 
disease (PD) and death. The length of each Markov cycle is one month. All 
patients start in the PF state and could move to other health states thereafter, 
according to the respective efficacy of each treatment. The model also takes into 
account the incidence of treatment-induced adverse events including grade 4 
haematological events and all grades nausea. Utility values associated with each 
health state and adverse events were used to estimate the number of QALYs 
associated with each treatment. Analyses were conducted from both a Canadian 
Ministry of Health (MoH) and a societal perspective. RESULTS: Compared with 
FR, BR is associated with ICERs of $38,821 per QALY and $45,809 per QALY, from a 
MoH and societal perspective respectively. Exhaustive sensitivity analyses 
confirm the robustness of the base-case scenario. Specifically, results of the 
probabilistic sensitivity analysis indicated that, according to a willingness to pay 
of $50,000, BR remains a cost-effective strategy in 100% and 90.2% of the 
simulations. CONCLUSIONS: This economic evaluation demonstrates that 
bendamustine in combination with rituximab is a cost-effective strategy in the 
treatment of relapsed iNHL/MCL when compared with fludarabine in 
combination with rituximab.  
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OBJECTIVES: Many breast cancer patients suffer from (severe) menopausal 
symptoms after an early onset of menopause caused by cancer treatment. The 
standard treatment for these complaints is hormone replacement therapy, 
which, however, is contraindicated for this group, as it may have tumor-
promoting effects. The aim of this study was to assess the cost-effectiveness of 
three interventions aimed at alleviating these symptoms: cognitive-behavioral 
therapy (CBT), physical exercise (PE), and the combination of both (CBT+PE). 
METHODS: A cost-effectiveness analysis was performed from a health care 
system perspective. The primary outcome was incremental health care costs 
(IHCC) per patient with a clinically relevant improvement after six months of 
treatments. The secondary outcome was incremental costs per quality-adjusted 
life years (QALYs) gained over a five-year time period. This was assessed using a 
Markov model, populated with data from a recent randomized controlled trial 
evaluating the effectiveness of CBT, PE, and CBT+PE in the clinical setting and 
additional cost data. The robustness of the results was analyzed through one-
way and probabilistic sensitivity analyses. RESULTS: IHCCs for alleviating one 
patient of the perceived symptom burden by a clinically relevant difference after 
six months of treatment were EUR€605 for CBT, EUR€1,847 for CBT+PT, and 
EUR€1,250 for PE alone, compared to the waiting list control group. CBT 
generated 0.009 additional QALYs at an additional cost of EUR€162, compared to 
the control group, leading to an Incremental Cost Utility Ratio (ICUR) of 
EUR€18,655 per QALY gained and The ICUR of CBT+PE was EUR€42,375 per QALY 
in comparison to the control group. CBT had a high probability (circa 61%) of 
being cost-effective at prevailing ceiling ratios. CONCLUSIONS: CBT is likely the 
most cost-effective of the three interventions investigated for alleviating 
treatment-induced menopausal symptoms in breast cancer patients.  
 
PCN78  
COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN 
IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S 
LYMPHOMA IN CANADA  
Lachaine J1, Beauchemin C1, Mathurin K1, Aissa F2 
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada Inc. , Montreal, QC, Canada  
OBJECTIVES: Non-Hodgkin’s lymphoma (NHL) is the most common lymphoma 
type, comprising approximately 90% of all malignant lymphomas, and is the 
seventh most commonly diagnosed cancer in North America. For patients with 
advanced, symptomatic indolent NHL (iNHL), rituximab is among the standard 
first-line induction therapy. For rituximab-refractory iNHL cases, alternative 
treatments are limited and comprised radioimmunotherapy treatments such as 
ibritumomab tiuxetan. The objective of this study was to assess the economic 
impact of bendamustine compared to ibritumomab tiuxetan in the treatment of 
rituximab-refractory iNHL in Canada. METHODS: A time-dependent Markov 
model with one-month cycles was constructed to assess the cost-effectiveness of 
bendamustine compared to ibritumomab tiuxetan in the treatment of rituximab-
refractory iNHL. The Markov transition model comprises three health states: 
progression-free (PF), progressive disease (PD) and death. All patients start in the 
PF state and could move to other health states thereafter, according to the 
respective efficacy of each treatment. The model also takes into account the 
incidence of treatment-induced adverse events including grade 4 haematological 
events and all grades nausea. Utility values associated with each health state 
and adverse events were used to estimate the number of QALYs associated with 
each treatment. Analyses were conducted from both a Canadian Ministry of 
Health (MoH) and a societal perspective over a lifetime horizon. RESULTS: 
Compared with ibritumomab tiuxetan, bendamustine is associated with ICERs of 
$35,490 per QALY and $42,130 per QALY, from a MoH and societal perspective 
respectively. Exhaustive sensitivity and complementary analyses confirm the 
robustness of the base-case scenario. Results of the probabilistic sensitivity 
analysis indicated that, according to a willingness to pay of $50,000, 
bendamustine remains a cost-effective strategy in 99.9% and 96.3% of the 
simulations. CONCLUSIONS: This economic evaluation demonstrates that 
